Sumitomo Pharma Co Ltd
TSE:4506

Watchlist Manager
Sumitomo Pharma Co Ltd Logo
Sumitomo Pharma Co Ltd
TSE:4506
Watchlist
Price: 591 JPY -6.49% Market Closed
Market Cap: 234.8B JPY
Have any thoughts about
Sumitomo Pharma Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one Sumitomo Pharma Co Ltd stock under the Base Case scenario is 795.72 JPY. Compared to the current market price of 591 JPY, Sumitomo Pharma Co Ltd is Undervalued by 26%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
795.72 JPY
Undervaluation 26%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Sumitomo Pharma Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Sumitomo Pharma Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Sumitomo Pharma Co Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Sumitomo Pharma Co Ltd

Provide an overview of the primary business activities
of Sumitomo Pharma Co Ltd.

What unique competitive advantages
does Sumitomo Pharma Co Ltd hold over its rivals?

What risks and challenges
does Sumitomo Pharma Co Ltd face in the near future?

Summarize the latest earnings call
of Sumitomo Pharma Co Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Sumitomo Pharma Co Ltd.

Provide P/S
for Sumitomo Pharma Co Ltd.

Provide P/E
for Sumitomo Pharma Co Ltd.

Provide P/OCF
for Sumitomo Pharma Co Ltd.

Provide P/FCFE
for Sumitomo Pharma Co Ltd.

Provide P/B
for Sumitomo Pharma Co Ltd.

Provide EV/S
for Sumitomo Pharma Co Ltd.

Provide EV/GP
for Sumitomo Pharma Co Ltd.

Provide EV/EBITDA
for Sumitomo Pharma Co Ltd.

Provide EV/EBIT
for Sumitomo Pharma Co Ltd.

Provide EV/OCF
for Sumitomo Pharma Co Ltd.

Provide EV/FCFF
for Sumitomo Pharma Co Ltd.

Provide EV/IC
for Sumitomo Pharma Co Ltd.

Show me price targets
for Sumitomo Pharma Co Ltd made by professional analysts.

What are the Revenue projections
for Sumitomo Pharma Co Ltd?

How accurate were the past Revenue estimates
for Sumitomo Pharma Co Ltd?

What are the Net Income projections
for Sumitomo Pharma Co Ltd?

How accurate were the past Net Income estimates
for Sumitomo Pharma Co Ltd?

What are the EPS projections
for Sumitomo Pharma Co Ltd?

How accurate were the past EPS estimates
for Sumitomo Pharma Co Ltd?

What are the EBIT projections
for Sumitomo Pharma Co Ltd?

How accurate were the past EBIT estimates
for Sumitomo Pharma Co Ltd?

Compare the revenue forecasts
for Sumitomo Pharma Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Sumitomo Pharma Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Sumitomo Pharma Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Sumitomo Pharma Co Ltd compared to its peers.

Compare the P/E ratios
of Sumitomo Pharma Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Sumitomo Pharma Co Ltd with its peers.

Analyze the financial leverage
of Sumitomo Pharma Co Ltd compared to its main competitors.

Show all profitability ratios
for Sumitomo Pharma Co Ltd.

Provide ROE
for Sumitomo Pharma Co Ltd.

Provide ROA
for Sumitomo Pharma Co Ltd.

Provide ROIC
for Sumitomo Pharma Co Ltd.

Provide ROCE
for Sumitomo Pharma Co Ltd.

Provide Gross Margin
for Sumitomo Pharma Co Ltd.

Provide Operating Margin
for Sumitomo Pharma Co Ltd.

Provide Net Margin
for Sumitomo Pharma Co Ltd.

Provide FCF Margin
for Sumitomo Pharma Co Ltd.

Show all solvency ratios
for Sumitomo Pharma Co Ltd.

Provide D/E Ratio
for Sumitomo Pharma Co Ltd.

Provide D/A Ratio
for Sumitomo Pharma Co Ltd.

Provide Interest Coverage Ratio
for Sumitomo Pharma Co Ltd.

Provide Altman Z-Score Ratio
for Sumitomo Pharma Co Ltd.

Provide Quick Ratio
for Sumitomo Pharma Co Ltd.

Provide Current Ratio
for Sumitomo Pharma Co Ltd.

Provide Cash Ratio
for Sumitomo Pharma Co Ltd.

What is the historical Revenue growth
over the last 5 years for Sumitomo Pharma Co Ltd?

What is the historical Net Income growth
over the last 5 years for Sumitomo Pharma Co Ltd?

What is the current Free Cash Flow
of Sumitomo Pharma Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Sumitomo Pharma Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Sumitomo Pharma Co Ltd

Current Assets 325.9B
Cash & Short-Term Investments 98B
Receivables 90.5B
Other Current Assets 137.5B
Non-Current Assets 543B
Long-Term Investments 41.3B
PP&E 59.7B
Intangibles 418.4B
Other Non-Current Assets 23.7B
Current Liabilities 498.4B
Accounts Payable 58.3B
Other Current Liabilities 440.2B
Non-Current Liabilities 209.6B
Long-Term Debt 133.4B
Other Non-Current Liabilities 76.2B
Efficiency

Earnings Waterfall
Sumitomo Pharma Co Ltd

Revenue
329.5B JPY
Cost of Revenue
-131.1B JPY
Gross Profit
198.5B JPY
Operating Expenses
-504.8B JPY
Operating Income
-306.4B JPY
Other Expenses
46.2B JPY
Net Income
-260.2B JPY

Free Cash Flow Analysis
Sumitomo Pharma Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Sumitomo Pharma Co Ltd's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
18/100
Profitability
Score

Sumitomo Pharma Co Ltd's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Sumitomo Pharma Co Ltd's solvency score is 28/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Positive Net Debt
Short-Term Solvency
28/100
Solvency
Score

Sumitomo Pharma Co Ltd's solvency score is 28/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Sumitomo Pharma Co Ltd

Wall Street analysts forecast Sumitomo Pharma Co Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Sumitomo Pharma Co Ltd is 547.89 JPY with a low forecast of 373.7 JPY and a high forecast of 787.5 JPY.

Lowest
Price Target
373.7 JPY
37% Downside
Average
Price Target
547.89 JPY
7% Downside
Highest
Price Target
787.5 JPY
33% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Sumitomo Pharma Co Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Sumitomo Pharma Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Sumitomo Pharma Co Ltd Logo
Sumitomo Pharma Co Ltd

Country

Japan

Industry

Pharmaceuticals

Market Cap

234.8B JPY

Dividend Yield

0%

Description

Sumitomo Dainippon Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. The company is headquartered in Osaka, Osaka-Fu and currently employs 6,822 full-time employees. The firm operates its business through four segments. The Japan segment is engaged in the manufacture, purchase, and sale of ethical drugs. The North American segment is engaged in the manufacture, purchase, and sale of ethical drugs and conducts research and development in the areas of oncology, urology, respiratory disease, and regenerative cell medicine. The China segment is engaged in the manufacture (small packaged products) and sale of ethical pharmaceuticals. The Overseas Others segment is engaged in the manufacture and sale of ethical pharmaceuticals in Europe. The segment also purchase and sell ethical pharmaceuticals in Southeast Asia and Taiwan, as well as provide information and collection activities for the Company's products. Other business includes manufacturing, purchasing, and sales of food ingredients, food additives and chemical product materials.

Contact

OSAKA-FU
Osaka
2-6-8, Dosho-machi, Chuo-ku
+81662035321.0
www.ds-pharma.co.jp

IPO

1949-05-16

Employees

6 822

Officers

Representative Director, President & CEO
Mr. Toru Kimura Ph.D.
Representative Director and Executive VP of Corporate Planning, Corp. Governance, HR & Accounting
Motoyuki Sakai
Mngg Exec. Officer of Global Data Design, Lgl Affairs. IP, IT Mgt, & Frontier Bus. Off.
Mr. Hiroyuki Baba
Executive Officer of Corporate Governance & Communications, VP and Head of Corporate Communications
Mr. Naoki Noguchi
Managing Executive Officer of Drug Research Division, Head of Japan Business Unit & Director
Mr. Yoshiharu Ikeda Ph.D.
E.O. of R. Aff., Med. Sci., C.R.C. & Q.A., Sr. VP, Hd of C.R.C. & Q.A. Div and Dp. Hd of Japan Bus.
Mr. Koichi Kozuki
Show More
Managing Executive Office, VP and Head of Business Development & Management
Dr. Shigeyuki Nishinaka Ph.D.
Executive Officer, Senior VP, Head of Drug Research Division & Senior Executive Research Director
Mr. Isao Shimizu
Executive Officer, Senior VP and Head of Technology Research & Development Division
Mr. Kenji Ueno
Managing Exe. Officer of Tech. R&D Div., Manufacturing Div. and Dep. Head of Japan Bus. Unit
Mr. Hideyuki Harada
Show Less

See Also

Discover More
What is the Intrinsic Value of one Sumitomo Pharma Co Ltd stock?

The intrinsic value of one Sumitomo Pharma Co Ltd stock under the Base Case scenario is 795.72 JPY.

Is Sumitomo Pharma Co Ltd stock undervalued or overvalued?

Compared to the current market price of 591 JPY, Sumitomo Pharma Co Ltd is Undervalued by 26%.

Back to Top